Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO1998051303) HIV AND CANCER TREATMENT
Latest bibliographic data on file with the International Bureau

Pub. No.: WO/1998/051303 International Application No.: PCT/US1997/021564
Publication Date: 19.11.1998 International Filing Date: 26.11.1997
Chapter 2 Demand Filed: 30.04.1998
IPC:
A61K 31/27 (2006.01) ,A61K 31/4184 (2006.01) ,A61K 31/4196 (2006.01) ,A61K 31/427 (2006.01) ,A61K 45/06 (2006.01)
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
21
Esters, e.g. nitroglycerine, selenocyanates
27
of carbamic or thiocarbamic acids, e.g. meprobamate, carbachol, neostigmine
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
33
Heterocyclic compounds
395
having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
41
having five-membered rings with two or more ring hetero atoms, at least one of which is nitrogen, e.g. tetrazole
4164
1,3-Diazoles
4184
condensed with carbocyclic rings, e.g. benzimidazoles
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
33
Heterocyclic compounds
395
having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
41
having five-membered rings with two or more ring hetero atoms, at least one of which is nitrogen, e.g. tetrazole
4196
1,2,4-Triazoles
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
33
Heterocyclic compounds
395
having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
41
having five-membered rings with two or more ring hetero atoms, at least one of which is nitrogen, e.g. tetrazole
425
Thiazoles
427
not condensed and containing further heterocyclic rings
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
45
Medicinal preparations containing active ingredients not provided for in groups A61K31/-A61K41/132
06
Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
Applicants:
THE PROCTER & GAMBLE COMPANY [US/US]; One Procter & Gamble Plaza Cincinnati, OH 45202, US (AllExceptUS)
CAMDEN, James, Berger [US/US]; US (UsOnly)
Inventors:
CAMDEN, James, Berger; US
Agent:
REED, T., David ; The Procter & Gamble Company 5299 Spring Grove Avenue Cincinnati, OH 45217, US
Priority Data:
60/046,72616.05.1997US
Title (EN) HIV AND CANCER TREATMENT
(FR) TRAITEMENT DU VIH ET DU CANCER
Abstract:
(EN) A method of treating HIV or other viral infections by administering a herbicide or fungicide or derivative thereof to an animal or human. The fungicides or herbicides can be used in conjunction with other treatments, e.g. with AZT or protease inhibitors for the treatment of HIV. For example, thiabendazole and chloropropham have been shown to quickly reduce the level of virus production from cell populations chronically infected with HIV-1 and the antiviral effect is maintained with continued compound exposure. This reduction of virus production occurs at concentrations which are non toxic to the host cell and which have no effect on the syntheses of cellular DNA, RNA and protein. Further, chronically infected cells treated for prolonged periods of time with thiabendazole and chloropropham were not super-infected with HIV. A method for inhibiting the growth of tumors and cancers in mammals comprising administering a herbicidal or fungicidal derivative is also disclosed herein. The fungicides or herbicides can be used in conjunction with other treatments, e.g. taxol for the treatment of breast cancer. Potentiators can also be included in the herbicidal or fungicidal composition. This method is particularly effective when the cancer or virus is an animal cell genetically modified by plant or fungus genetic material. A chemotherapeutic agent can also be administered first to significantly reduce the size of the cancer and then the treatment with the herbicide or fungicide is used. These methods are particularly effective when the cancer or virus is a mutated cell comprising plant or fungal genetic material.
(FR) L'invention porte sur un procédé de traitement du VIH ou d'autres infections virales, ce procédé consistant à administrer un herbicide ou un fongicide, ou un dérivé de celui-ci, à un animal ou à un être humain. Les fongicides ou herbicides peuvent être utilisés conjointement avec d'autres traitements tels que AZT ou des inhibiteurs de protéases dans le traitement du VIH. Par exemple, thiabendazole et chloroprophame se sont révélés avoir un effet réducteur rapide sur le niveau de production de virus à partir de populations cellulaires chroniquement infectées par le VIH-1, l'effet antiviral étant maintenu grâce à une exposition continue du composé. Cette réduction de la production des virus s'effectue à des concentrations qui sont non toxiques pour la cellule hôte et qui n'ont aucun effet sur les synthèses de l'ADN cellulaire, l'ARN et la protéine. De plus, les cellules chroniquement infectées, traitées sur des durées prolongées avec thiabendazole et chloroprophame, n'étaient pas surinfectées par le VIH. L'invention concerne également un procédé d'inhibition de la prolifération des tumeurs et des cancers chez les mammifères, ce procédé consistant à administrer un dérivé herbicide ou fongicide. Les fongicides ou herbicides peuvent être utilisés conjointement avec d'autres traitements tels que taxol dans le traitement du cancer du sein. La composition herbicide ou fongicide peut également renfermer des agents de potentialisation. Ce procédé est notamment efficace lorsque le cancer ou le virus est une cellule animale génétiquement modifiée par un matériau génétique végétal ou fongique. Il est également possible d'administrer d'abord un agent chimiothérapeutique de façon à réduire considérablement la grosseur du cancer, puis d'avoir recours au traitement avec l'herbicide ou le fongicide. Ces procédés sont notamment efficaces lorsque le cancer ou le virus est une cellule mutée comprenant un matériau génétique végétal ou fongique.
Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW
African Regional Intellectual Property Organization (ARIPO) (GH, KE, LS, MW, SD, SZ, UG, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)
Also published as:
CZPV1999-1249NO19991701NZ335158SK46999TR1999/01530MXPA/a/1999/003321
KR1020000049064VN4342EP0954309JP2000510156 CN1254281CA2268848
AU1998074029AU2001038790